Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $8.30, but opened at $8.71. Capricor Therapeutics shares last traded at $8.81, with a volume of 1,964,773 shares changing hands.
Analysts Set New Price Targets
CAPR has been the subject of a number of research reports. Oppenheimer restated an "outperform" rating on shares of Capricor Therapeutics in a research note on Thursday, October 8th. Alliance Global Partners lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a research report on Tuesday, July 28th. Wall Street Zen downgraded Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Roth Capital reaffirmed a "neutral" rating and set a $10.50 target price (up from $7.00) on shares of Capricor Therapeutics in a research note on Friday. Finally, Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, September 1st. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of "Hold" and an average price target of $30.09.
Read Our Latest Analysis on Capricor Therapeutics
Capricor Therapeutics Price Performance
The stock has a market capitalization of $498.86 million, a P/E ratio of -3.25 and a beta of 0.80. The stock's fifty day moving average is $8.08 and its two-hundred day moving average is $19.79.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.29). Analysts expect that Capricor Therapeutics, Inc. will post -2.39 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. KBC Group NV purchased a new position in shares of Capricor Therapeutics during the first quarter valued at $44,000. Activest Wealth Management lifted its stake in Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 2,000 shares during the last quarter. Quantinno Capital Management LP grew its position in Capricor Therapeutics by 16.8% in the first quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company's stock worth $440,000 after acquiring an additional 2,083 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 21.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company's stock worth $164,000 after purchasing an additional 3,036 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Capricor Therapeutics by 41.2% during the 1st quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company's stock valued at $541,000 after purchasing an additional 5,195 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.